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Abstract
Background: The directly observed therapy-short course (DOTS) strategy was introduced in Shaanxi province,
China to improve tuberculosis (TB) control by means of improved case detection (target: > = 70%) and treatment
success rates (target: > = 85%) in new smear positive (SS+) TB patients. At a provincial level the targets were both
reached in 2005. However in 30 (28%) out of 107 counties of Shaanxi province the cure rate was below 85%. This
study aimed to investigate patient and treatment characteristics associated with non-cure after tuberculosis (TB)
treatment in these counties.
Methods: In this case-control study, new smear positive TB cases in 30 counties with a cure rate <85% were
included. Cured patients were compared to non-cured patients using logistic regression analysis to assess
determinants for non-cure.
Results: Of the 659 patients included, 153 (23.2%) did not have cure as treatment outcome. Interruption of
treatment was most strongly associated with non-cure (OR = 8.7, 95% CI 3.9-18.4). Other independent risk factors
were co-morbidity, low education level, lack of appetite as an initial symptom of TB disease, diagnosis of TB
outside of the government TB control institutes, missing sputum re-examinations during treatment, and not having
a treatment observer. Twenty-six percent of patients did not have a treatment observer. The non-cure rate was
better for those with a doctor (odds ratio (OR) 0.38, 95% confidence interval (CI) 0.17-0.88) as treatment observer
than for those with a family member (OR 0.62, 95%CI 0.37-1.03). The main reason for interrupted treatment
mentioned by patients was presence of adverse effects during treatment (46.5%).
Conclusions: Interruption of treatment was most strongly associated with non-cure. Although treatment
observation by medical staff is preferred, in order to diminish the proportion of patients who do not have a
treatment observer and thereby reduce the proportion of patients who interrupt treatment, we suggest making it
possible for family members, after sufficient training, to be treatment observers in remote areas where it is
logistically difficult to have village doctors observe treatment for all patients.
Background
Shaanxi Province is located in the western part of China,
covering 20.6 thousand square kilometers with a popula-
tion of 36.7 million. It is one of the less developed areas
in China. The notification rate for new sputum smear
positive (SS+) tuberculosis (TB) cases was 29 per
100,000 in Shaanxi province in 2005. The Directly
Observed Treatment Short-course (DOTS) strategy,
aiming at high-quality TB control, has been implemen-
ted in Shaanxi from 2002 onward. Two of the basic
components of the DOTS strategy are to realize a high
detection rate and a high treatment success rate, in
order to control the TB epidemic. Full DOTS coverage
in Shaanxi was achieved in 2005. At that time, the SS+
case detection rate in Shaanxi was estimated to be 88%,
and the overall cure rate for new SS+ TB cases was also
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patients in 30 (28%) out of the 107 counties of Shaanxi
province was below 85%. Most of these counties are
located in poor and remote areas of the province.
Several reasons and risk factors for poor TB treatment
outcomes have been reported. High age, male sex, low
income, no or limited access to transport, distance from
home to the treatment centre, incomplete treatment
compliance, limited interest in information about the
disease and its treatment, limited social support, multi-
drug resistance and diabetes mellitus have all been
found to be related to unsuccessful treatment outcomes
[1-7]. It is not clear which factors are major contributors
to non-cure of TB patients in the remote and poor areas
of Shaanxi Province. This study aims to provide insight
into determinants for non-cure among new smear-posi-
tive TB patients in the 30 counties in Shaanxi province
that did not achieve a 85% cure rate in 2005 despite
implementation of the DOTS strategy.
Methods
Study population and data collection
New smear positive TB cases who were registered at the
TB clinic in the Center for Diseases Prevention and
Control (CDC) in 30 counties with low cure rate (<85%)
in 2005 from June 1 2006 to March 31 2007 were eligi-
ble for participation in this study. A random sample of
540 patients was drawn for inclusion. Patients were
interviewed 6-9 months after registration at the
CDC. They had all started standardized treatment
(2H3R3Z3E3/4H3R3) directly after registration. Informa-
tion on demographic status, TB disease onset, co-mor-
bidity, the treatment period, as well as on patients’
knowledge on TB was collected from the patients by
means of standardized questionnaires. Patients are sup-
posed to come for sputum re-examinations at 2, 5, and
6 months after the start of treatment. Information on
sputum re-examinations and treatment outcome was
obtained from the patient records. Cure was defined
according to the international classification [8], i.e. clini-
cal response and two subsequent sputum acid-fast bacilli
(AFB) smear negative results, the last one at completion
of treatment.
The investigators used standardized questionnaires to
interview the patients during scheduled home visits.
Assistants rechecked the data after the interviews to
ensure completeness.
Sampling
Sample size calculations were performed using Stat Calc
software in Epi-Info 6. A sample size of 540 patients
was required to be able to detect a difference of 15%
(50% vs. 65%) in a risk factor between two groups with
95% confidence and 80% power, and assuming a rate of
loss to follow-up of 10% (e.g. non-participation and
incomplete questionnaires).
During the study period, we observed an increased
cure rate in the study population compared to 2005. To
raise the power of the study to detect risk factors for
non-cure, we decided to additionally include all remain-
ing uncured patients registered from June 1 2006 to
March 31 2007 that were not sampled already. To avoid
information bias, the interviewers were not informed
that the additionally included patients all were non-
cured.
Data analysis
Data were double entered in Epi data 3.0, checked for
consistency and mistakes were corrected. Statistical ana-
lysis was performed in SPSS 13.0. Cured patients were
compared to non-cured patients to assess characteristics
associated with non-cure. Variables with a p-value < 0.2
in a univariate logistic regression model were included
in a multivariate model. The final model was obtained
by backward selection of the most parsimonious model
based on the log likelihood ratio test (p < 0.05).
Ethical considerations
The principles of the Helsinki Declaration were taken
into account. Written, informed consent was obtained
from all study subjects. The study was approved by the
medical ethical committee of the Chinese TB Control
Association.
Results
Characteristics of the patients
During the study period, 659 new smear positive pul-
monary TB cases were included, including 45 non-cured
patients added later. All patients sampled could be
traced and were interviewed at their homes after making
an appointment except twenty patients that had died
since registration.
Of these 659 patients, 153 (23.2%) were not cured.
Thirty-seven (5.6%) completed treatment but did not
submit a sputum sample for smear examination at the
end of treatment, 82 (12.4%) defaulted from treatment
for which 65 had a known reason such as side-effects,
20 (3.0%) died, 9 (1.4%) failed treatment, and 5 (0.8%)
transferred out. As it was not possible to obtain reliable
information on the twenty patients that had died since
registration, they were excluded from the analyses.
Most patients were male (67.3%) and were farmers
(62.6%), (Table 1). Of all cases, 39.3% did not have med-
ical insurance which means that they needed to pay for
additional medical costs, e.g. for treatment of side-
effects, besides smear-examinations and anti-TB drugs
which are provided free of charge. Seven percent of the
patients had co-morbidity like cardio-vascular diseases,
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patients (43.5%) reported side effects during TB treat-
ment, such as renal disorder (1.4%), jaundice (1.8%),
decline in auditory function (5.0%), liver problems
(5.3%), joint pain and/or swelling (6.0%), skin rash
(11.0%) and so on. In total 46 (7.2%) patients inter-
rupted treatment for a median of 17.5 days before conti-
nuing. Twenty-six percent of patients did not have a
treatment observer.
Univariate analysis of risk factors for non-cure
In the univariate analysis, age over 60 years, being illiter-
ate, not having a job, fever and loss of appetite as initial
symptoms, diagnosis of TB outside the CDC, co-mor-
bidity, not having a treatment observer, missing more
doses of the TB drugs, interrupted treatment, having
side effects during treatment, long distance from the
patients house to the medical center and having no
or irregular sputum examinations were statistically
significantly associated with a lower cure rate (Table 1
and Table 2). The population over 60 years had a signif-
icantly higher prevalence of co-morbidity (11.4% vs.
5 . 7 % ) .A l s o ,i na g e dp a t i e n t ss i d ee f f e c t sw e r em o r ef r e -
quent (54.2% vs. 42.1%), (Table 3).
Multivariate analysis of risk factors for non-cure
Independent risk factors associated with non-cure were
being illiterate, having an intermediate level of expendi-
ture, being diagnosed with TB outside the CDC, loss of
appetite being an initial symptom of TB, co-morbidity,
not having a treatment observer (compared to having a
doctor as observer), interruption of treatment, and not
or only having irregular sputum re-examinations in the
CDC (Table 4).
Although being a farmer, high age, having fever as an
initial symptom and presence of side-effects during
treatment were statistically significant risk factors for
non-cure in the multivariate model, removal of these
Table 1 Patient related characteristics associated with non-cure after anti-tuberculosis treatment in patients
diagnosed in 30 remote and poor counties in Shaanxi province, China
Patient characteristic n(%) Treatment result OR 95% CI p-value
Uncured (%) Cured (%)
Sex 0.92
Female 209 (32.7) 43 (20.6) 166 (79.4) 1
Male 430 (67.3) 90 (20.9) 340 (79.1) 1.02 0.68-1.54
Age (years) < 0.01
≤25 141 (22.1) 26 (18.4) 115 (81.6) 1
26-50 251 (39.3) 38 (15.1) 213 (84.9) 0.79 0.46-1.37
51-60 105 (16.4) 26 (24.8) 79 (75.2) 1.46 0.79-2.69
>60 142 (22.2) 43 (30.3) 99 (69.7) 1.92 1.10-3.35
Education level < 0.01
Illiterate 95 (14.9) 32 (33.7) 63 (66.3) 1
Primary school 147 (23.1) 31 (21.1) 116 (78.9) 0.53 0.29-0.94
Junior high school 265 (41.6) 38 (14.3) 227 (85.7) 0.33 0.19-0.57
Senior high school 106 (16.6) 22 (20.8) 84 (79.2) 0.52 0.27-0.97
College and above 24 (3.8) 10 (41.7) 14 (58.3) 1.41 0.56-3.52
Occupation 0.04
Farmer 400 (62.6) 77 (19.3) 323 (80.7) 1
Factory worker 98 (15.3) 16 (16.3) 82 (83.7) 0.82 0.45-1.48
Other profession worker 141 (22.1) 40 (28.4) 101 (71.6) 1.66 1.07-2.59
Annual income (CNY)* 0.01
≤1000 187 (29.3) 38 (20.3) 149 (79.7) 1
1001-2000 195 (30.5) 28 (14.4) 167 (85.6) 0.66 0.39-1.12
>2000 257 (40.2) 67 (26.1) 190 (73.9) 1.38 0.88-2.17
Medical insurance 0.52
No (own expense) 247 (39.3) 49 (19.8) 198 (80.2) 1
Yes 382 (60.7) 84 (22.0) 298 (78.0) 1.14 0.77-1.69
Distance from patient’s home to county TB dispensary < 0.01
≤5 km 461(72.1) 81(17.6) 380(82.4) 1
>5 km 178(27.9) 52(29.2) 126(70.8) 1.93 1.29-2.89
* Currency rate: US$ 100 equaled about 780 CNY during the study.
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as tested with the log likelihood ratio test, so we
excluded them from the final model.
Interruption of treatment was most strongly associated
with non-cure (OR = 8.7, 95% CI 3.9-18.4). Having side
effects was the main reason for interrupting treatment
(46.5%, Figure 1).
Several reasons were mentioned by patients for not
going to the clinic for (regular) sputum re-examination.
The most common reasons mentioned were: having
mild symptoms, not thinking it was necessary to have
regular re-examinations, and financial or traffic difficul-
ties (Figure 2). Thirty-nine percent of the respondents
did not provide a reason.
Discussion
It is assumed that by increasing the detection rate and
cure rate to at least 70% and 85% respectively, transmis-
sion of TB and morbidity and mortality of TB disease
will be reduced, and the TB epidemic would be
Table 2 Treatment related characteristics associated with non-cure after anti-tuberculosis treatment in patients
diagnosed in 30 remote and poor counties in Shaanxi province, China
Treatment characteristic n(%) Treatment result OR 95% CI p-value
Uncured (%) Cured (%)
Co-morbidity < 0.01
No 562 (93.0) 95 (16.9) 467 (83.1) 1
Yes 42 (7.0) 22 (52.4) 20 (47.6) 5.41 2.84-10.30
Fever 0.04
No 426 (66.7) 99(23.9) 327 (76.1) 1
Yes 213 (33.3) 34 (16.0) 179 (84.0) 1.59 1.04-2.45
Loss of appetite < 0.01
No 497 (77.8) 92 (18.5) 405 (81.5)
Yes 142 (22.2) 41 (28.9) 101 (71.1) 1.79 1.17-2.74
Institute where TB was diagnosed 0.01
CDC 142 (22.2) 60 (17.1) 290 (82.9) 1
Other 497 (77.8) 73 (25.3) 216 (74.7) 1.63 1.11-2.40
DOT supervisor < 0.01
No supervisor 169 (26.4) 48 (28.4) 121 (71.6) 1
Family 367 (57.4) 73 (19.9) 294 (80.1) 0.63 0.41-0.95
Doctor 103 (16.1) 12 (11.7) 91 (88.3) 0.33 0.17-0.66
Number of times forgotten to take drugs < 0.01
none 541 (84.7) 104 (19.2) 437 (80.8) 1
≤9 times 76 (11.9) 18 (23.7) 58 (76.3) 1.30 0.74-2.31
>9 times 22 (3.4) 11 (50.0) 11 (50.0) 4.20 1.77-9.96
Maximum number of subsequently missed doses 0.01
None 542 (84.8) 105 (19.4) 437 (80.6) 1
≤ 3 times 64 (10.0) 14 (21.9) 50 (78.1) 1.17 0.62-2.19
>3 times 33 (5.2) 14 (42.4) 19 (57.6) 3.07 1.49-6.32
Interruption of treament < 0.01
No 591 (92.5) 102 (17.3) 489 (82.7) 1
Yes 48 (7.5) 31 (64.6) 17 (35.4) 8.74 4.66-16.40
Severity of side effects* < 0.01
None 361 (56.5) 66 (18.3) 295 (81.7) 1
Severe 54 (8.5) 27 (50.0) 27 (50.0) 4.47 2.46-8.12
Medium 41 (6.4) 14 (34.1) 27 (65.9) 2.32 1.15-4.66
Light 183 (28.6) 26 (14.2) 157 (85.8) 0.74 0.45-1.21
Sputum re-examination** < 0.01
Regular 442 (69.2) 57 (12.9) 385 (87.1) 1
Irregular 155 (24.3) 59 (38.1) 96 (61.9) 4.15 2.71-6.36
None 42 (6.6) 17 (40.5) 25 (59.5) 4.59 2.34-9.03
* The severity of side effects is based on the patient’s opinion.
** Regular sputum re-examination: New smear positive cases performing sputum re-examination at the end of the 2nd, 5th and 6th month of the therapy,
according to the guidelines.
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Shaanxi province in China is assumed to be sufficient,
but the cure rate did not reach the target of 85% in all
counties in the province.
Many factors were observed to be related to non-cure
in this study, including patient, diagnosis and treatment
related factors. Independent risk factors for non-cure of
new smear-positive TB patients in the selected counties
with a low cure rate in Shaanxi province were: presence
of co-morbidity, loss of appetite as an initial symptom
of TB, diagnosis outside the government TB control
institute, failing to perform regular sputum re-examina-
tions, temporary interruption of treatment, and no
direct observation of treatment by medical staff.
Among the independent risk factors for non-cure,
interruption of treatment was the most important one
(OR = 8.7). The results are supported by results from
other studies [2,8,11]. One study from China showed
that there were different reasons for treatment interrup-
tion such as side-effects and financial difficulties in rela-
tion to treatment [12]. Patients who interrupt treatment
a r em o r el i k e l yt ob e c o m ei n f e c t i o u sa g a i na n da c q u i r e
drug resistance [13,14]. Thus, improvement of adher-
ence to treatment is important to control (drug-resis-
tant) TB.
Co-morbidity was the other major predictor for non-
cure in our study population (OR = 5.8). Our result
showed that the aged population had a higher preva-
lence of co-morbidity and side effects, as shown before
[15]. So there is a correlation between high age, co-mor-
bidity and presence of side-effects. Although co-morbid-
ity, high age and side-effects were all significantly
associated with non-cure, co-morbidity turned out to be
the most important predictor for non-cure in our study.
The pre-existence of other diseases, especially diabetes
mellitus, has been shown to be associated with treat-
ment failure before [6]. Older age has been associated
with unsuccessful treatment outcome before, although
not consistently [2-4,7].
Hernandez-Garduno and Perez-Guzman hypothesized
that chronic lack of appetite can be a potential indepen-
dent risk factor for TB disease and can affect TB treat-
ment [16]. Our result confirmed that a lack of appetite
as a symptom of TB is risk factor for poor treatment
outcomes.
Not having the standard sputum re-examinations was
associated with non cure. The reasons given by patients
for missing re-examinations, indicated that many
patients may not have been aware of the importance of
re-examination.
Patients with village doctors as treatment observer had
a decreased risk of non-cure compared to patients
Table 3 Association between age and co-morbidityand
adverse events in TB patients in Shaanxi province, China
Age
n >60 year
(%)
≤60 year
(%)
OR 95% CI p-value
Co-morbidity 0.02
No 562 117(20.8) 445(79.2) 1
Yes 42 15(35.7) 27(64.3) 2.11 1.09-
4.10
Adverse
events
0.01
No 353 65(18.4) 288(81.6) 1
Yes 286 77(26.9) 209(73.1) 1.63 1.10-
2.42
Table 4 Multivariate analysis on risk factors for non-cure
after anti-tuberculosis treatment in patients diagnosed in
30 remote and poor counties in Shaanxi province, China
Characteristic OR 95% CI
Education level
Illiterate 1
Primary school 0.50 0.24-1.02
Junior high school 0.34 0.18-0.67
Senior high school 0.38 0.17-0.84
College and above 1.67 0.56-4.94
Annual income (CNY)
≤1000 1
1001-2000 0.71 0.37-1.37
>2000 1.51 0.85-2.68
Co-morbidity
No 1
Yes 5.80 2.77-12.15
Loss of appetite
No 1
Yes 1.77 1.03-3.06
Institute where TB was diagnosed
CDC 1
Other 1.79 1.10-2.92
DOT supervisor
No supervisor 1
Family 0.62 0.37-1.03
Doctor 0.38 0.17-0.88
Interruption of treatment
No 1
Yes 8.41 3.85-18.37
Sputum re-examinations
Regular 1
Irregular 2.56 1.52-4.32
No 2.10 0.90-4.91
*Currency rate: US $100 equals about 780 CNY during the study.
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family members also had a decreased risk of non-cure
(p = 0.07), although the risk was slightly higher than for
those patients observed by village doctors. Daniel et al.
studied the risk factors associated with default from
tuberculosis treatment in Nigeria and also suggested
that alternative strategies such as the use of family
members to oversee treatment may be desirable [4]. Our
results support this point.
Contradictory results exist on the effect of poverty and
male sex on treatment outcomes [4,7]. In our study
these were not found to be independent risk factors.
Individual immune status [17], multidrug resistance
[18,19], and the Mycobacterium tuberculosis Beijing gen-
otype have been associated with treatment failure [20],
but we were unable to study these factors in our study.
A limitation of our study is that we mostly had to rely
on self-reported status of sensitive issues like interrup-
tion of treatment, and had to ask retrospectively about
treatment issues like number of missed doses and side-
effects. Also, although we did not inform interviewers of
treatment outcomes, it is possible that they did find out
during the interviews. By means of careful training of
interviewers and interviewing with fixed questions we
Figure 1 Reasons for interruption of treatment as reported by patients (n = 43). Patients could provide more than one reason.
Figure 2 Reasons for the absence and irregular sputum re-examination as reported by patients (n = 187). Patients could provide more
than one reason.
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ing data collection we decided to additionally include all
remaining non-cured cases in the study population as
cure rates were higher than in the previous year. Exclu-
sion of the 45 non-cured cases added later to the study
sample led to similar results with the same major risk
factors as co-morbidity, treatment observation, TB diag-
nosis institute and attendance to sputum smear exami-
nations still included in the final multivariate model.
Our study has provided us with useful insights on fac-
tors influencing non-cure in the poor and remote areas
of Shaanxi province. Based on the results, we recom-
mend that patient education should be enhanced by
clinic doctors to improve the patients understanding of
their disease and its treatment and to improve compli-
ance to treatment and re-examinations. Furthermore,
during treatment, more attention should be paid to
monitoring of side-effects. Limiting fees for treatment of
side effects may reduce interruption of treatment and
increase cure rates. Treatment observation of patients,
including observation by the county and village doctors
should be enhanced. Because of the poor transportation
possibilities to reach the TB clinics and wide dispersal
of TB patients, we suggest that DOT supervision in
remote areas can be performed by family members after
they are trained to ensure quality of treatment
observation.
Conclusions
Interruption of treatment and co-morbidity were the
most important predictors of non-cure. Appropriate
patient education and support, and treatment of co-
existing diseases may increase compliance, prevent inter-
ruption of treatment and hereby increase the cure rate.
Twenty-six percent of patients did not have a treatment
observer. Although treatment observation by medical
staff is preferred, in remote areas where it is logistically
difficult to have village doctors observe treatment of all
patients, we suggest making it possible for family mem-
bers to become treatment observers after they are prop-
erly trained.
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